Abstract
Alzheimer’s disease (AD) is the most common form of neurodegenerative dementia. Researchers have long been focused on the cortical pathology of AD, since the most important pathologic features are the senile plaques found in the cortex, and the neurofibrillary tangles and neuronal loss that begin in the entorhinal cortex and the hippocampus. In addition to these gray matter (GM) structures, histopathological studies indicate that the white matter (WM) is also a good target for both the early diagnosis of AD and for monitoring disease progression. The fornix is a WM bundle that constitutes a core element of the limbic circuits, and is one of the most important anatomical structures related to memory. Functional and anatomical features of the fornix have naturally captured researchers’ attention as possible diagnostic and prognostic markers of AD. Indeed, neurodegeneration of the fornix has been histologically observed in AD, and growing evidence indicates that the alterations seen in the fornix are potentially a good marker to predict future conversion from mild cognitive impairment (MCI) to AD, and even from cognitively normal individuals to AD. The degree of alteration is correlated with the degree of memory impairment, indicating the potential for the use of the fornix as a functional marker. Moreover, there have been attempts to stimulate the fornix using deep brain stimulation (DBS) to augment cognitive function in AD, and ongoing research has suggested positive effects of DBS on brain glucose metabolism in AD patients. On the other hand, disease specificity for fornix degeneration, methodologies to evaluate fornix degeneration, and the clinical significance of the fornix DBS, especially for the long-term impact on the quality of life, are mostly unknown and need to be elucidated.
Introduction
Alzheimer’s disease (AD) research has targeted beta-amyloid and tau pathologies as diagnostic or progression markers. White matter (WM) shows less pathologic evidence of beta-amyloid or tau protein; nonetheless, alterations are seen in WM as well. Among WM bundles reportedly abnormal in AD, the fornix is especially interesting because robust and consistent alterations have been demonstrated. These could predict future gray matter (GM) atrophy and conversion from mild cognitive impairment (MCI) to AD, and even from cognitively normalcy to AD. Moreover, there are ongoing efforts to impact the biologic processes of AD by stimulating the fornix using deep brain stimulation (DBS). This review focuses on the fornix as a potential alternative diagnostic and prognostic marker, as well as a potential therapeutic target in AD.
WM alterations seen in AD
Histopathological studies have revealed various types of WM alterations in AD. Symmetrical WM changes compatible with incomplete infarction, independent of the GM changes, have been reported. These WM changes are partly explained by co-existing small vessel disease (Brun and Englund, 1986; Englund et al., 1988). WM changes are also related to cerebral amyloid angiopathy of AD, supporting a vascular contribution to the WM alterations (Haglund and Englund, 2002). Chronic hypoxia caused by vascular alterations might induce oxidative stress that could damage axonal membranes and myelin, and the reactivity of oligodendroglia to such damage (Back et al., 2011). However, in preclinical AD, WM alterations are independent of vascular alterations (de la Monte, 1989). In addition, degeneration of the WM was more obvious than that of the GM in early stages (de la Monte, 1989), suggesting that WM alteration precedes GM pathology. Indeed, the earliest disease-related anatomical changes have been observed in the axons and dendrites of AD animal model (Gunawardena and Goldstein, 2001; Pigino et al., 2003; Stokin et al., 2005; Chevalier-Larsen and Holzbaur, 2006). Therefore, mechanisms that cause the early pathological changes, aside from vascular alterations, might exist. According to the updated amyloid cascade hypothesis (Hardy and Selkoe, 2002), one of the high upstream events is production of soluble beta-amyloid oligomers, been discovered to be toxic to WM structure and function (Lue et al., 1999; Xu et al., 2001; Lee et al., 2004). This could be a major cause of the primary WM alterations in AD (Roher et al., 2002; Chalmers et al., 2005) at least in early stages.
In addition to widespread WM alterations, structure-specific WM alterations have been observed, especially in limbic structures (Damoiseaux et al., 2009; Acosta-Cabronero et al., 2010; Smith et al., 2010; Liu et al., 2011). This might at least partly be explained by aberrant axonal transport due to misregulation of tau seen in early disease stage (Alonso et al., 1994; Ebneth et al., 1998; Dawson et al., 2010), with resultant tau aggregation that is closely related to neurodegeneration (Braak and Braak, 1995). Since the neurodegeneration of AD usually propagates systematically from the transentorhinal area to limbic structures, to neocortex at the most advanced stage, associated Wallerian-like degeneration (Bossy-Wetzel et al., 2004; Coleman, 2005) likely follows the same order, which might explain structure-specific WM alterations in AD (Bramblett et al., 1992).
Congruent with histopathological findings, WM alteration has been observed in vivo using various imaging modalities. Among these, diffusion tensor imaging (DTI) is one of the most effective modalities for the investigation of the WM anatomy since DTI has the ability to visualize WM fibers, based on directionality, and has the capability to provide detailed information about microscopic organization of the fibers. A meta-analysis of DTI studies indicated that WM alterations in AD are widespread throughout the brain (Sexton et al., 2011), particularly in limbic fibers, direct connections to the medial temporal lobe and the most vulnerable WM structures (Rose et al., 2000; Kantarci et al., 2001; Medina et al., 2006; Ringman et al., 2007; Stahl et al., 2007; Zhang et al., 2007; Zhou et al., 2008; Damoiseaux et al., 2009; Mielke et al., 2009; Salat et al., 2010). WM damage quantified by DTI has been correlated with atrophy in anatomically connected GM areas in AD patients, but the correlation was not robust in patients with amnestic MCI (Agosta et al., 2011). These findings support the histopathological observation that primary WM alterations may precede both GM degeneration, as well as secondary degenerative processes of the WM after neuronal loss. Based on the evidence about WM pathology in AD, Sachdev et al. proposed incorporating WM alterations into the model (Jack et al., 2010) of the pathophysiological cascade in AD (Sachdev et al., 2013).
Why is the fornix important?
The fornices are WM bundles that originate from the bilateral hippocampi, merge at the midline of the brain, again divide into the left and right side, then into precommissural and postcommissural fibers, terminating at the septal nuclei, nucleus accumbens (precommissural fornix), and hypothalamus (postcommissural fornix). The fornix constitutes a core element of the limbic circuit that is vulnerable in AD, and one of the most important anatomical structures related to episodic memory, impairment of which is an initial symptom of AD (Hopper and Vogel, 1976; Mehraein and Rothemund, 1976). The fornix is also related to the cholinergic dysfunction characteristic of AD (Milner and Amaral, 1984; Wenk et al., 1987; Ransmayr et al., 1989; Sara, 1989; Schegg et al., 1989; Bunce et al., 2003; Colom et al., 2010). These functional and anatomical features have naturally captured researcher attention seeking diagnostic and prognostic markers of AD. Indeed, alterations of the fornix, such as demyelination or axonal loss, were reported as early as in 1976 (Hopper and Vogel, 1976) and have been consistently identified in AD (Ringman et al., 2007; Teipel et al., 2007; Mielke et al., 2009; Acosta-Cabronero et al., 2010; Salat et al., 2010; Liu et al., 2011; Douaud et al., 2013).
The other important anatomical feature of the fornix, compared to other WM areas, is its location. The body of the fornix is readily identifiable in the mid-sagittal plane of a brain MRI, without other WM structures adjacent to it. For research using brain MRI, this feature is particularly important. The thickness of the fornix can be easily measured on structural MRI, using T1- and T2-weighted images. Generally, identification of the boundaries of WM structures on structural MRI is not easy because the boundaries between adjacent WM structures are often invisible: the fornix is one of several exceptions. DTI is a good choice with which to identify the boundaries of WM bundles. Although a drawback of DTI is susceptibility to B0 distortion, especially for areas close to air cavities (e.g., nasal and oral cavities, frontal, ethmoid, sphenoid, and maxillary sinuses, and mastoid antrum), the fornix is less affected because there is a sufficient distance from the fornix to these air cavities. The anatomical location is also attractive from a neurosurgical point of view, since the fornix is surgically accessible for implanting electrodes for DBS (see Section Treatment), while other limbic structures are not easily accessible.
Imaging study of the fornix in AD
Region-of-interest studies
Atrophy of the fornix measured using T1-weighted MRI has often been reported in AD (Callen et al., 2001; Copenhaver et al., 2006), although the onset of this atrophy has been a subject of debate. Fletcher et al. (2013) reported that atrophy of the fornix is a strong predictor of conversion from normal cognition to MCI or AD, suggesting that atrophy is present in the fornix at an early disease stage, before clinical manifestations. Abnormalities in the fornix have also been identified using DTI. A reduction of fractional anisotropy (FA) and an increase in diffusivity in the fornix is a robust and consistent finding in AD as demonstrated with manual ROI- analysis (Ringman et al., 2007; Mielke et al., 2009; Oishi et al., 2012), and the extent of the changes in DTI-derived parameters have been correlated with cognitive decline (Mielke et al., 2009; Oishi et al., 2012). Notably, FA reduction was already present in an asymptomatic gene carrier of familial AD who went on to develop AD in the future (Ringman et al., 2007). Longitudinal observation of cognitively normal elderly or individuals with amnestic MCI indicated that reduced fornix FA predicts conversion from normal cognition to amnestic MCI and from amnestic MCI to AD (Oishi et al., 2012). Moreover, lower fornix FA predicted later cognitive decline and hippocampal atrophy (Mielke et al., 2012). These studies suggest that volume loss and FA reduction of the fornix is one of the earliest anatomical changes in AD that happens before clinical manifestations.
Whole-brain studies
While region-of-interest analysis is a good choice when there are specific hypotheses (e.g., the fornix is affected in AD), the drawback is the hypothesis dependency. To evaluate the spatial specificity of these findings, whole-brain analysis is a good choice. Voxel-based analysis is one of the most widely used approaches for whole-brain analysis, and has been used to evaluate regional abnormalities in WM volume (Li et al., 2008; Balthazar et al., 2009; Guo et al., 2010; Serra et al., 2010; Yoon et al., 2011) or in DTI-derived parameters, such as anisotropy and diffusivity (Head et al., 2004; Medina et al., 2006; Xie et al., 2006; Teipel et al., 2007; Zhang et al., 2009). Although cross-sectional group comparisons have identified widespread WM abnormalities in AD, the above studies failed to identify reduced volume or FA in the fornix, except for a study that used multivariate analysis (Teipel et al., 2007). The main explanation is probably inaccuracy in image normalization: the accuracy of automated non-linear registration used in these studies was limited for thin structures like the fornix, in which only a few pixels of misregistration cause significant loss of sensitivity to detect differences between groups (Oishi et al., 2009). A common approach to solve this problem is to apply Tract-Based Spatial Statistics (TBSS; Smith et al., 2006), in which WM tracts are “skeletonized” to summarize the anatomy of WM structures, from which statistics are calculated. Since the scalar values perpendicular to the skeleton are projected onto the skeleton, the effect of WM misregistration is largely ameliorated. Most of the whole brain TBSS studies applied to AD have, indeed, identified an FA reduction in the fornix, as well as in other limbic fibers, even in early-symptomatic patients or in individuals at high risk for developing AD (Damoiseaux et al., 2009; Honea et al., 2009; Stricker et al., 2009; Zarei et al., 2009; Acosta-Cabronero et al., 2010; Bosch et al., 2010; Smith et al., 2010; Liu et al., 2011; Douaud et al., 2013).
Application of large deformation diffeomorphic metric mapping (LDDMM) to DTI is another way to increase the sensitivity of whole-brain analysis, by which registration accuracy of the WM bundles could be increased. By using LDDMM, significant volume loss, FA reduction, and increases in mean diffusivity (MD) and radial diffusivity were detected in the fornix of individuals with AD (Oishi et al., 2011a,b). Figure 1 is an example of such an analysis, designed to find brain areas with AD-specific WM alterations. This analysis indicates significant FA reduction in the fornix, the splenium of the corpus callosum, as well as in several small areas in superficial WM in the frontal lobes. To further increase sensitivity, multivariate models (Ashburner and Kloppel, 2011), such as principal component analysis (PCA; Teipel et al., 2007), or to apply voxel-grouping methods, such as atlas-based analysis (ABA; Oishi et al., 2009), were applied: all of these detected abnormalities in the fornix in AD. These whole-brain studies using sophisticated approaches consistently indicate the fornix as the “hotspot”, in which the earliest anatomical changes begin (“Fornix First” (Landhuis, 2013)), and where the most robust changes are seen in AD.
Figure 1
Pitfalls and issues in fornix image analysis
Misregistration
As mentioned previously, TBSS is currently a standard method by which to ameliorate WM tract misregistration. However, in patients with ventricular enlargement, like AD, the fornix is strongly deformed by the elevated and stretched corpus callosum, which results in uncorrectable misregistration, even with TBSS (Hattori et al., 2012). Therefore, careful interpretation is needed for AD studies. An inverse-projection of TBSS results onto original images is a simple method with which to identify invalid results caused by misregistration.
One solution to reduce the impact of erroneous mapping of voxels, and the consequent mis-parcellation of target structures, is to adopt multi-atlas approaches. Rather than using a single atlas for anatomical labeling, this approach uses multiple atlases to compute the likelihoods of labels, which are then fused to create an anatomical parcellation map for each image. This approach, which accounts for variations in brain anatomy, has been adapted to parcellate WM structures in DTI (Tang et al., 2014) with high accuracy even for individuals with ventricular enlargement. Applicability of the multi-atlas label fusion method to accurately define the fornix is a promising approach, which needs to be developed in the future with automated image analysis of AD.
Contamination of signal from cerebrospinal fluid
The fornix is prone to partial volume effects caused by contamination of signal from the cerebrospinal fluid (CSF), since it is a thin bundle that runs through the lateral ventricles that are filled with CSF. The effect is especially seen in individuals with AD because of atrophy, and thus, increased CSF signal in each voxel (Pfefferbaum and Sullivan, 2003; Metzler-Baddeley et al., 2012; Berlot et al., 2014). The greater diffusivity in CSF relative to the WM structures leads to false elevation of diffusivity values and a false reduction in FA values (Alexander et al., 2001; Vos et al., 2011). Therefore, reduced FA or increased diffusivity identified in the DTI studies of AD probably reflects pathological alterations of the fornix itself plus the partial volume effects caused by atrophy. Although this dual effect (atrophy + microstructural change) on the DTI parameters might make DTI a sensitive tool with which to detect early anatomical changes related to AD, it complicates inferences about the underlying anatomical changes. There have been several attempts to ameliorate the effects of CSF contamination in order to draw inferences about the microstructural changes in the WM structures, such as CSF-suppressed diffusion imaging (Kwong et al., 1991), or the free water elimination and mapping method that is applicable at the post-acquisition stage (Pasternak et al., 2009), both of which could detect alteration of the fornix in AD (Kantarci et al., 2010; Fletcher et al., 2014). Investigations of underlying changes in WM structures seem to suggest a good indication for the use these advanced methods (Metzler-Baddeley et al., 2012).
Cause of fornix degeneration and DTI parameters of choice
Since the contribution of each factor (see WM alterations seen in AD) to the degeneration of the fornix might vary depending on the degree of disease progression, longitudinal observation of the histopathology, from the preclinical to the advanced stages, is especially important. Use of the AD model in animals is an option for such longitudinal observation. A reduced size of the fornix is seen in the PDAPP mice (Gonzalez-Lima et al., 2001) and transgenic APP/PS1 mice (Delatour et al., 2006), and immunohistochemistry shows the presence of increasing amyloidosis and related microgliosis and astrogliosis (Maheswaran et al., 2009). However, longitudinal changes in the size of the fornix differ depending on the type of AD model mice. Since type and variations in gene mutation are relevant to the pathophysiology of AD model animals, and considerable differences are seen between human AD and AD model animals, human in vivo neuroimaging studies are important to understand the pathophysiological underpinnings. For early AD, diffusion measures (MD and axial and radial diffusivities) could detect the widespread pathology of AD more sensitively than FA (Acosta-Cabronero et al., 2010; Oishi et al., 2011a). However, for the fornix, there seems to be a tendency that a decrease in FA is more sensitive than an increase in diffusivity measures. Whether there is a difference in pathophysiology between the fornix and other WM areas remains to be elucidated.
Clinical applications of the findings seen in the fornix
Diagnosis and prediction
There are several hurdles when applying research findings to clinical practice. Research studies are based on selected participants with strict inclusion and exclusion criteria, and usually age- and gender-matched participants are recruited as controls. However, routine image-based diagnosis is almost exclusively performed by qualitative visual inspection, which is applied to each individual for clinical decision-making. Although numerous publications link AD to degeneration in the fornix, volume or the diffusivity are not quantified in daily practice because of the time-consuming nature of this process, and the inconsistent quantification methods used in research. The fornix sign, a discoloration of the fornix observed on color-coded FA maps of AD (Oishi et al., 2012), is one attempt to define qualitative image signs applicable to clinical images (Figure 2). Although sensitivity was limited, specificity was high. The positive likelihood ratio differentiating AD from controls and hence the ability to predict conversion of cognitively normal individuals to amnestic MCI, or from amnestic MCI to AD, was strong. However, further efforts are needed to identify appropriate scan parameters, cut-off values for the diagnosis and prediction, as well as to investigate degeneration in the fornix seen in other types of dementia.
Figure 2
Given that individuals with different types of memory complaints visit clinics, and physicians need to identify the etiology of the memory complaint for medical decision-making, the value of imaging signs that can separate AD from individuals with normal cognition are limited. Rather, clinically relevant imaging signs must provide clues that can be used to separate AD from other diseases that cause memory impairment. Indeed, the fornix might be affected by tumors, infections, inflammations (Yamamoto et al., 1990), metabolic abnormalities, vascular diseases (Molino et al., 2014), malformations, trauma, and hydrocephalus (Hattori et al., 2012) (for review, Thomas et al., 2011). Psychiatric diseases, such as schizophrenia and bipolar affective disorder (Oertel-Knöchel et al., 2014), or medical conditions, such as heart failure (Wu et al., 2007), also cause damage in the fornix. Less is known about the involvement of the fornix in other neurodegenerative dementias, such as frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and corticobasal degeneration (CBD). A study indicated substantial FA reduction in the fornix of the behavioral variant FTD that correlated with memory decline (Hornberger et al., 2012), and other studies have indicated that the fornix is affected in Pick’s disease, FTD with tau mutation, or TAR-DNA-binding protein-43 type C pathology, but not for FTD caused by a progranulin mutation or with fused-in-sarcoma protein accumulation (Rohrer et al., 2011; Hornberger et al., 2012). Changes in the fornix were not detected by group comparison between DLB and control groups (Kantarci et al., 2010), or between CBD and control groups (Rohrer et al., 2011), but other research has reported reduced FA in the fornix of some DLB patients, especially for those with hippocampal atrophy (Firbank et al., 2011). The appropriate clinical use of imaging modalities for the evaluation of the fornix is, therefore, an important future direction.
Treatment
Inspired by neuroimaging evidence about early impairment of the limbic circuit seen in AD, and an unexpected augmentation of recollection during the hypothalamic/fornix DBS performed on a patient with obesity (Hamani et al., 2008), DBS of the fornix has been proposed as a novel therapy for AD to improve the neuronal circuitry involved in memory (Laxton et al., 2010). Based on the hypothesis that an important aspect of AD is that it is a system-level disorder affecting several integrated pathways related to memory and cognition (Lyketsos et al., 2012), and supported by rodent studies indicating that DBS improved memory and produced hippocampal neurogenesis (Toda et al., 2008; Hamani et al., 2011), a clinical trial evaluating the effect of DBS targeting the fornix is ongoing. Electrodes are placed adjacent to the fornix for high frequency electronic stimulation, with the hope of an immediate effect (direct effects of stimulating the fornix) and a disease-modifying effect (neurogenesis). Although its number of participants was small, the earlier Phase 1 trial suggested improved glucose metabolism in the posterior cortical areas, especially in cognitively improved participants after fornix DBS (Laxton et al., 2010; Smith et al., 2012). The assessment of long-term impact on cognitive function, activities of daily living, quality of life, and mortality is an important future direction.
Statements
Acknowledgments
The authors thank Ms. Mary McAllister for help with manuscript editing. This study was supported by NIH grants, R01AG031348, R01AG042165 (Constantine G. Lyketsos), R21AG033774, P50AG005146, and R01HD065955 (Kenichi Oishi). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIA, NICHD, or NIH.
Conflict of interest
Constantine G. Lyketsos has received support from the following organizations Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, Glaxo-Smith-Kline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, Bristol-Myers, and Novartis. Constantine G. Lyketsos has served as a consultant/advisor for Astra-Zeneca, Glaxo-Smith-Kline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, and Genentech. Constantine G. Lyketsos has received honorarium or travel support from Pfizer, Forest, Glaxo-Smith-Kline, and Health Monitor. This arrangement has been approved by the Johns Hopkins University in accordance with its conflict of interest policies.
References
1
Acosta-CabroneroJ.WilliamsG. B.PengasG.NestorP. J. (2010). Absolute diffusivities define the landscape of white matter degeneration in Alzheimer’s disease. Brain133, 529–539. 10.1093/brain/awp257
2
AgostaF.PievaniM.SalaS.GeroldiC.GalluzziS.FrisoniG. B.et al. (2011). White matter damage in Alzheimer disease and its relationship to gray matter atrophy. Radiology258, 853–863. 10.1148/radiol.10101284
3
AlexanderA. L.HasanK. M.LazarM.TsurudaJ. S.ParkerD. L. (2001). Analysis of partial volume effects in diffusion-tensor MRI. Magn. Reson. Med.45, 770–780. 10.1002/mrm.1105
4
AlonsoA. C.ZaidiT.Grundke-IqbalI.IqbalK. (1994). Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc. Natl. Acad. Sci. U S A91, 5562–5566. 10.1016/0197-4580(94)92603-4
5
AshburnerJ.KloppelS. (2011). Multivariate models of inter-subject anatomical variability. Neuroimage.56, 422–439. 10.1016/j.neuroimage.2010.03.059
6
BackS. A.KroenkeC. D.ShermanL. S.LawrenceG.GongX.TaberE. N.et al. (2011). White matter lesions defined by diffusion tensor imaging in older adults. Ann. Neurol.70, 465–476. 10.1002/ana.22484
7
BalthazarM. L.YasudaC. L.PereiraF. R.PedroT.DamascenoB. P.CendesF. (2009). Differences in grey and white matter atrophy in amnestic mild cognitive impairment and mild Alzheimer’s disease. Eur. J. Neurol.16, 468–474. 10.1111/j.1468-1331.2008.02408.x
8
BerlotR.Metzler-BaddeleyC.JonesD. K.O’sullivanM. J. (2014). CSF contamination contributes to apparent microstructural alterations in mild cognitive impairment. Neuroimage92, 27–35. 10.1016/j.neuroimage.2014.01.031
9
BoschB.Arenaza-UrquijoE. M.RamiL.Sala-LlonchR.JunquéC.Solé-PadullésC.et al. (2010). Multiple DTI index analysis in normal aging, amnestic MCI and AD. Relationship with neuropsychological performance. Neurobiol. Aging33, 61–74. 10.1016/j.neurobiolaging.2010.02.004
10
Bossy-WetzelE.SchwarzenbacherR.LiptonS. A. (2004). Molecular pathways to neurodegeneration. Nat. Med.10(Suppl.), S2–S9. 10.1038/nm1067
11
BraakH.BraakE. (1995). Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol. Aging16, 271–278; discussion 278–284. 10.1016/0197-4580(95)00021-6
12
BramblettG. T.TrojanowskiJ. Q.LeeV. M. (1992). Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau-isoforms (A68 proteins). Lab. Invest.66, 212–222.
13
BrunA.EnglundE. (1986). A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann. Neurol.19, 253–262. 10.1002/ana.410190306
14
BunceJ. G.SabolekH. R.ChrobakJ. J. (2003). Intraseptal infusion of oxotremorine impairs memory in a delayed-non-match-to-sample radial maze task. Neuroscience121, 259–267. 10.1016/s0306-4522(03)00462-7
15
CallenD. J.BlackS. E.GaoF.CaldwellC. B.SzalaiJ. P. (2001). Beyond the hippocampus: MRI volumetry confirms widespread limbic atrophy in AD. Neurology57, 1669–1674. 10.1212/wnl.57.9.1669
16
ChalmersK.WilcockG.LoveS. (2005). Contributors to white matter damage in the frontal lobe in Alzheimer’s disease. Neuropathol. Appl. Neurobiol.31, 623–631. 10.1111/j.1365-2990.2005.00678.x
17
Chevalier-LarsenE.HolzbaurE. L. (2006). Axonal transport and neurodegenerative disease. Biochim. Biophys. Acta1762, 1094–1108. 10.1016/j.bbadis.2006.04.002
18
ColemanM. (2005). Axon degeneration mechanisms: commonality amid diversity. Nat. Rev. Neurosci.6, 889–898. 10.1038/nrn1788
19
ColomL. V.CastañedaM. T.BañuelosC.PurasG.García-HernándezA.HernandezS.et al. (2010). Medial septal beta-amyloid 1-40 injections alter septo-hippocampal anatomy and function. Neurobiol. Aging31, 46–57. 10.1016/j.neurobiolaging.2008.05.006
20
CopenhaverB. R.RabinL. A.SaykinA. J.RothR. M.WishartH. A.FlashmanL. A.et al. (2006). The fornix and mammillary bodies in older adults with Alzheimer’s disease, mild cognitive impairment and cognitive complaints: a volumetric MRI study. Psychiatry Res.147, 93–103. 10.1016/j.pscychresns.2006.01.015
21
DamoiseauxJ. S.SmithS. M.WitterM. P.Sanz-ArigitaE. J.BarkhofF.ScheltensP.et al. (2009). White matter tract integrity in aging and Alzheimer’s disease. Hum. Brain Mapp.30, 1051–1059. 10.1002/hbm.20563
22
DawsonH. N.CantillanaV.JansenM.WangH.VitekM. P.WilcockD. M.et al. (2010). Loss of tau elicits axonal degeneration in a mouse model of Alzheimer’s disease. Neuroscience169, 516–531. 10.1016/j.neuroscience.2010.04.037
23
de la MonteS. M. (1989). Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer’s disease. Ann. Neurol.25, 450–459. 10.1002/ana.410250506
24
DelatourB.GuéganM.VolkA.DhenainM. (2006). In vivo MRI and histological evaluation of brain atrophy in APP/PS1 transgenic mice. Neurobiol. Aging27, 835–847. 10.1016/j.neurobiolaging.2005.04.011
25
DouaudG.MenkeR. A.GassA.MonschA. U.RaoA.WhitcherB.et al. (2013). Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer’s disease. J. Neurosci.33, 2147–2155. 10.1523/jneurosci.4437-12.2013
26
EbnethA.GodemannR.StamerK.IllenbergerS.TrinczekB.MandelkowE. (1998). Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria and endoplasmic reticulum: implications for Alzheimer’s disease. J. Cell Biol.143, 777–794. 10.1083/jcb.143.3.777
27
EnglundE.BrunA.AllingC. (1988). White matter changes in dementia of Alzheimer’s type. Biochemical and neuropathological correlates. Brain111(Pt. 6), 1425–1439. 10.1093/brain/111.6.1425
28
FirbankM. J.BlamireA. M.TeodorczukA.TeperE.MitraD.O’brienJ. T. (2011). Diffusion tensor imaging in Alzheimer’s disease and dementia with Lewy bodies. Psychiatry Res.194, 176–183. 10.1016/j.pscychresns.2011.08.002
29
FletcherE.CarmichaelO.PasternakO.Maier-HeinK. H.DecarliC. (2014). Early brain loss in circuits affected by Alzheimer’s disease is predicted by fornix microstructure but may be independent of gray matter. Front. Aging Neurosci.6:106. 10.3389/fnagi.2014.00106
30
FletcherE.RamanM.HuebnerP.LiuA.MungasD.CarmichaelO.et al. (2013). Loss of fornix white matter volume as a predictor of cognitive impairment in cognitively normal elderly individuals. JAMA Neurol.70, 1389–1395. 10.1001/jamaneurol.2013.3263
31
Gonzalez-LimaF.BerndtJ. D.VallaJ. E.GamesD.ReimanE. M. (2001). Reduced corpus callosum, fornix and hippocampus in PDAPP transgenic mouse model of Alzheimer’s disease. Neuroreport12, 2375–2379. 10.1097/00001756-200108080-00018
32
GunawardenaS.GoldsteinL. S. (2001). Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron32, 389–401. 10.1016/s0896-6273(01)00496-2
33
GuoX.WangZ.LiK.LiZ.QiZ.JinZ.et al. (2010). Voxel-based assessment of gray and white matter volumes in Alzheimer’s disease. Neurosci. Lett.468, 146–150. 10.1016/j.neulet.2009.10.086
34
HaglundM.EnglundE. (2002). Cerebral amyloid angiopathy, white matter lesions and Alzheimer encephalopathy - a histopathological assessment. Dement. Geriatr. Cogn. Disord.14, 161–166. 10.1159/000063606
35
HamaniC.McandrewsM. P.CohnM.OhM.ZumstegD.ShapiroC. M.et al. (2008). Memory enhancement induced by hypothalamic/fornix deep brain stimulation. Ann. Neurol.63, 119–123. 10.1002/ana.21295
36
HamaniC.StoneS. S.GartenA.LozanoA. M.WinocurG. (2011). Memory rescue and enhanced neurogenesis following electrical stimulation of the anterior thalamus in rats treated with corticosterone. Exp. Neurol.232, 100–104. 10.1016/j.expneurol.2011.08.023
37
HardyJ.SelkoeD. J. (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science297, 353–356. 10.1126/science.1072994
38
HattoriT.ItoK.AokiS.YuasaT.SatoR.IshikawaM.et al. (2012). White matter alteration in idiopathic normal pressure hydrocephalus: tract-based spatial statistics study. AJNR Am. J. Neuroradiol.33, 97–103. 10.3174/ajnr.a2706
39
HeadD.BucknerR. L.ShimonyJ. S.WilliamsL. E.AkbudakE.ConturoT. E.et al. (2004). Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type: evidence from diffusion tensor imaging. Cereb. Cortex14, 410–423. 10.1093/cercor/bhh003
40
HoneaR. A.VidoniE.HarshaA.BurnsJ. M. (2009). Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. J. Alzheimers Dis.18, 553–564. 10.3233/JAD-2009-1163
41
HopperM. W.VogelF. S. (1976). The limbic system in Alzheimer’s disease. A neuropathologic investigation. Am. J. Pathol.85, 1–20.
42
HornbergerM.WongS.TanR.IrishM.PiguetO.KrilJ.et al. (2012). In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer’s disease. Brain135, 3015–3025. 10.1093/brain/aws239
43
JackC. R.Jr.KnopmanD. S.JagustW. J.ShawL. M.AisenP. S.WeinerM. W.et al. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol.9, 119–128. 10.1016/s1474-4422(09)70299-6
44
KantarciK.AvulaR.SenjemM. L.SamikogluA. R.ZhangB.WeigandS. D.et al. (2010). Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI. Neurology74, 1814–1821. 10.1212/wnl.0b013e3181e0f7cf
45
KantarciK.JackC. R.Jr.XuY. C.CampeauN. G.O’brienP. C.SmithG. E.et al. (2001). Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. Radiology219, 101–107. 10.1148/radiology.219.1.r01ap14101
46
KwongK. K.MckinstryR. C.ChienD.CrawleyA. P.PearlmanJ. D.RosenB. R. (1991). CSF-suppressed quantitative single-shot diffusion imaging. Magn. Reson. Med.21, 157–163. 10.1002/mrm.1910210120
47
LandhuisE. (2013). Fornix First—Atrophy Foreshadows Decline in Normal Aging? Available online at: http://www.alzforum.org/news/research-news/fornix-first-atrophy-foreshadows-decline-normal-aging. Accessed on June 19 2014.
48
LaxtonA. W.Tang-WaiD. F.McandrewsM. P.ZumstegD.WennbergR.KerenR.et al. (2010). A phase I trial of deep brain stimulation of memory circuits in Alzheimer’s disease. Ann. Neurol.68, 521–534. 10.1002/ana.22089
49
LeeJ. T.XuJ.LeeJ. M.KuG.HanX.YangD. I.et al. (2004). Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J. Cell Biol.164, 123–131. 10.1083/jcb.200307017
50
LiS.PuF.ShiF.XieS.WangY.JiangT. (2008). Regional white matter decreases in Alzheimer’s disease using optimized voxel-based morphometry. Acta Radiol.49, 84–90. 10.1080/02841850701627181
51
LiuY.SpulberG.LehtimäkiK. K.KönönenM.HallikainenI.GröhnH.et al. (2011). Diffusion tensor imaging and tract-based spatial statistics in Alzheimer’s disease and mild cognitive impairment. Neurobiol. Aging32, 1558–1571. 10.1016/j.neurobiolaging.2009.10.006
52
LueL. F.KuoY. M.RoherA. E.BrachovaL.ShenY.SueL.et al. (1999). Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am. J. Pathol.155, 853–862. 10.1016/s0002-9440(10)65184-x
53
LyketsosC. G.TargumS. D.PendergrassJ. C.LozanoA. M. (2012). Deep brain stimulation: a novel strategy for treating Alzheimer’s disease. Innov. Clin. Neurosci.9, 10–17.
54
MaheswaranS.BarjatH.RueckertD.BateS. T.HowlettD. R.TillingL.et al. (2009). Longitudinal regional brain volume changes quantified in normal aging and Alzheimer’s APP x PS1 mice using MRI. Brain Res.1270, 19–32. 10.1016/j.brainres.2009.02.045
55
MedinaD.Detoledo-MorrellL.UrrestaF.GabrieliJ. D.MoseleyM.FleischmanD.et al. (2006). White matter changes in mild cognitive impairment and AD: a diffusion tensor imaging study. Neurobiol. Aging27, 663–672. 10.1016/j.neurobiolaging.2005.03.026
56
MehraeinP.RothemundE. (1976). [Neuroanatomical correlates of the amnestic syndrome (author’s transl)]. Arch. Psychiatr. Nervenkr.222, 153–176.
57
Metzler-BaddeleyC.O’sullivanM. J.BellsS.PasternakO.JonesD. K. (2012). How and how not to correct for CSF-contamination in diffusion MRI. Neuroimage59, 1394–1403. 10.1016/j.neuroimage.2011.08.043
58
MielkeM. M.KozauerN. A.ChanK. C.GeorgeM.ToroneyJ.ZerrateM.et al. (2009). Regionally-specific diffusion tensor imaging in mild cognitive impairment and Alzheimer’s disease. Neuroimage46, 47–55. 10.1016/j.neuroimage.2009.01.054
59
MielkeM. M.OkonkwoO. C.OishiK.MoriS.TigheS.MillerM. I.et al. (2012). Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer’s disease. Alzheimers Dement.8, 105–113. 10.1016/j.jalz.2011.05.2416
60
MilnerT. A.AmaralD. G. (1984). Evidence for a ventral septal projection to the hippocampal formation of the rat. Exp. Brain Res.55, 579–585. 10.1007/bf00235290
61
MolinoI.CavaliereC.SalvatoreE.QuarantelliM.ColucciL.FasanaroA. M. (2014). Is anterior communicating artery syndrome related to fornix lesions?J. Alzheimers Dis.42, S199–S204. 10.3233/JAD-132648
62
Oertel-KnöchelV.ReinkeB.AlvesG.JurcoaneA.WenzlerS.PrvulovicD.et al. (2014). Frontal white matter alterations are associated with executive cognitive function in euthymic bipolar patients. J. Affect. Disord.155, 223–233. 10.1016/j.jad.2013.11.004
63
OishiK.AkhterK.MielkeM.CeritogluC.ZhangJ.JiangH.et al. (2011a). Multi-modal MRI analysis with disease-specific spatial filtering: initial testing to predict mild cognitive impairment patients who convert to Alzheimer’s disease. Front. Neurol.2:54. 10.3389/fneur.2011.00054
64
OishiK.FariaA.JiangH.LiX.AkhterK.ZhangJ.et al. (2009). Atlas-based whole brain white matter analysis using large deformation diffeomorphic metric mapping: application to normal elderly and Alzheimer’s disease participantstlas. Neuroimage46, 486–499. 10.1016/j.neuroimage.2009.01.002
65
OishiK.MielkeM. M.AlbertM.LyketsosC. G.MoriS. (2011b). DTI analyses and clinical applications in Alzheimer’s disease. J. Alzheimers Dis.26(Suppl. 3), 287–296. 10.3233/JAD-2011-0007
66
OishiK.MielkeM. M.AlbertM.LyketsosC. G.MoriS. (2012). The fornix sign: a potential sign for Alzheimer’s disease based on diffusion tensor imaging. J. Neuroimaging22, 365–374. 10.1111/j.1552-6569.2011.00633.x
67
PasternakO.SochenN.GurY.IntratorN.AssafY. (2009). Free water elimination and mapping from diffusion MRI. Magn. Reson. Med.62, 717–730. 10.1002/mrm.22055
68
PfefferbaumA.SullivanE. V. (2003). Increased brain white matter diffusivity in normal adult aging: relationship to anisotropy and partial voluming. Magn. Reson. Med.49, 953–961. 10.1002/mrm.10452
69
PiginoG.MorfiniG.PelsmanA.MattsonM. P.BradyS. T.BusciglioJ. (2003). Alzheimer’s presenilin 1 mutations impair kinesin-based axonal transport. J. Neurosci.23, 4499–4508.
70
RansmayrG.CerveraP.HirschE.RubergM.HershL. B.DuyckaertsC.et al. (1989). Choline acetyltransferase-like immunoreactivity in the hippocampal formation of control subjects and patients with Alzheimer’s disease. Neuroscience32, 701–714. 10.1016/0306-4522(89)90291-1
71
RingmanJ. M.O’neillJ.GeschwindD.MedinaL.ApostolovaL. G.RodriguezY.et al. (2007). Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer’s disease mutations. Brain130, 1767–1776. 10.1093/brain/awm102
72
RoherA. E.WeissN.KokjohnT. A.KuoY. M.KalbackW.AnthonyJ.et al. (2002). Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer’s disease. Biochemistry41, 11080–11090. 10.1021/bi026173d
73
RohrerJ. D.LashleyT.SchottJ. M.WarrenJ. E.MeadS.IsaacsA. M.et al. (2011). Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain134, 2565–2581. 10.1093/brain/awr198
74
RoseS. E.ChenF.ChalkJ. B.ZelayaF. O.StrugnellW. E.BensonM.et al. (2000). Loss of connectivity in Alzheimer’s disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J. Neurol. Neurosurg. Psychiatry69, 528–530. 10.1136/jnnp.69.4.528
75
SachdevP. S.ZhuangL.BraidyN.WenW. (2013). Is Alzheimer’s a disease of the white matter?Curr. Opin. Psychiatry26, 244–251. 10.1097/YCO.0b013e32835ed6e8
76
SalatD. H.TuchD. S.Van Der KouweA. J.GreveD. N.PappuV.LeeS. Y.et al. (2010). White matter pathology isolates the hippocampal formation in Alzheimer’s disease. Neurobiol. Aging31, 244–256. 10.1016/j.neurobiolaging.2008.03.013
77
SaraS. J. (1989). Noradrenergic-cholinergic interaction: its possible role in memory dysfunction associated with senile dementia. Arch. Gerontol. Geriatr. Suppl.1, 99–108.
78
ScheggK. M.NielsenS.ZweigR. M.PeacockJ. H. (1989). Decrease in membrane-bound G4 form of acetylcholinesterase in postmortem Alzheimer brain. Prog. Clin. Biol. Res.317, 437–452.
79
SerraL.CercignaniM.LenziD.PerriR.FaddaL.CaltagironeC.et al. (2010). Grey and white matter changes at different stages of Alzheimer’s disease. J. Alzheimers Dis.19, 147–159. 10.3233/JAD-2010-1223
80
SextonC. E.KaluU. G.FilippiniN.MackayC. E.EbmeierK. P. (2011). A meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer’s disease. Neurobiol. Aging32, 2322.e5–2322.e18. 10.1016/j.neurobiolaging.2010.05.019
81
SmithC. D.ChebroluH.AndersenA. H.PowellD. A.LovellM. A.XiongS.et al. (2010). White matter diffusion alterations in normal women at risk of Alzheimer’s disease. Neurobiol. Aging31, 1122–1131. 10.1016/j.neurobiolaging.2008.08.006
82
SmithS. M.JenkinsonM.Johansen-BergH.RueckertD.NicholsT. E.MackayC. E.et al. (2006). Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage31, 1487–1505. 10.1016/j.neuroimage.2006.02.024
83
SmithG. S.LaxtonA. W.Tang-WaiD. F.McandrewsM. P.DiaconescuA. O.WorkmanC. I.et al. (2012). Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease. Arch. Neurol.69, 1141–1148. 10.1001/archneurol.2012.590
84
StahlR.DietrichO.TeipelS. J.HampelH.ReiserM. F.SchoenbergS. O. (2007). White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques. Radiology243, 483–492. 10.1148/radiol.2432051714
85
StokinG. B.LilloC.FalzoneT. L.BruschR. G.RockensteinE.MountS. L.et al. (2005). Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease. Science307, 1282–1288. 10.1126/science.1105681
86
StrickerN. H.SchweinsburgB. C.Delano-WoodL.WierengaC. E.BangenK. J.HaalandK. Y.et al. (2009). Decreased white matter integrity in late-myelinating fiber pathways in Alzheimer’s disease supports retrogenesis. Neuroimage45, 10–16. 10.1016/j.neuroimage.2008.11.027
87
TangX.YoshidaS.HsuJ.HuismanT. A.FariaA. V.OishiK.et al. (2014). Multi-contrast multi-atlas parcellation of diffusion tensor imaging of the human brain. PLoS One9:e96985. 10.1371/journal.pone.0096985
88
TeipelS. J.StahlR.DietrichO.SchoenbergS. O.PerneczkyR.BokdeA. L.et al. (2007). Multivariate network analysis of fiber tract integrity in Alzheimer’s disease. Neuroimage34, 985–995. 10.1016/j.neuroimage.2006.07.047
89
ThomasA. G.KoumellisP.DineenR. A. (2011). The fornix in health and disease: an imaging review. Radiographics31, 1107–1121. 10.1148/rg.314105729
90
TodaH.HamaniC.FawcettA. P.HutchisonW. D.LozanoA. M. (2008). The regulation of adult rodent hippocampal neurogenesis by deep brain stimulation. J. Neurosurg.108, 132–138. 10.3171/jns/2008/108/01/0132
91
VosS. B.JonesD. K.ViergeverM. A.LeemansA. (2011). Partial volume effect as a hidden covariate in DTI analyses. Neuroimage55, 1566–1576. 10.1016/j.neuroimage.2011.01.048
92
WenkG.HugheyD.BoundyV.KimA.WalkerL.OltonD. (1987). Neurotransmitters and memory: role of cholinergic, serotonergic and noradrenergic systems. Behav. Neurosci.101, 325–332. 10.1037//0735-7044.101.3.325
93
WuM.RosanoC.Lopez-GarciaP.CarterC. S.AizensteinH. J. (2007). Optimum template selection for atlas-based segmentation. Neuroimage34, 1612–1618. 10.1016/j.neuroimage.2006.07.050
94
XieS.XiaoJ. X.GongG. L.ZangY. F.WangY. H.WuH. K.et al. (2006). Voxel-based detection of white matter abnormalities in mild Alzheimer disease. Neurology66, 1845–1849. 10.1212/01.wnl.0000219625.77625.aa
95
XuJ.ChenS.AhmedS. H.ChenH.KuG.GoldbergM. P.et al. (2001). Amyloid-beta peptides are cytotoxic to oligodendrocytes. J. Neurosci.21:RC118.
96
YamamotoT.KurobeH.KawamuraJ.HashimotoS.NakamuraM. (1990). Subacute dementia with necrotising encephalitis selectively involving the fornix and splenium. Retrograde development of Alzheimer’s neurofibrillar tangles in the subiculum. J. Neurol. Sci.96, 159–172. 10.1016/0022-510x(90)90129-b
97
YoonB.ShimY. S.HongY. J.KooB. B.KimY. D.LeeK. O.et al. (2011). Comparison of diffusion tensor imaging and voxel-based morphometry to detect white matter damage in Alzheimer’s disease. J. Neurol. Sci.302, 89–95. 10.1016/j.jns.2010.11.012
98
ZareiM.DamoiseauxJ. S.MorgeseC.BeckmannC. F.SmithS. M.MatthewsP. M.et al. (2009). Regional white matter integrity differentiates between vascular dementia and Alzheimer disease. Stroke40, 773–779. 10.1161/strokeaha.108.530832
99
ZhangY.SchuffN.DuA. T.RosenH. J.KramerJ. H.Gorno-TempiniM. L.et al. (2009). White matter damage in frontotemporal dementia and Alzheimer’s disease measured by diffusion MRI. Brain132, 2579–2592. 10.1093/brain/awp071
100
ZhangY.SchuffN.JahngG. H.BayneW.MoriS.SchadL.et al. (2007). Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology68, 13–19. 10.1212/01.wnl.0000250326.77323.01
101
ZhouY.DoughertyJ. H.Jr.HubnerK. F.BaiB.CannonR. L.HutsonR. K. (2008). Abnormal connectivity in the posterior cingulate and hippocampus in early Alzheimer’s disease and mild cognitive impairment. Alzheimers Dement.4, 265–270. 10.1016/j.jalz.2008.04.006
Summary
Keywords
Alzheimer’s disease, mild cognitive impairment, diffusion tensor imaging, deep brain stimulation, fornix, limbic system, magnetic resonance imaging, white matter
Citation
Oishi K and Lyketsos CG (2014) Alzheimer’s disease and the fornix. Front. Aging Neurosci. 6:241. doi: 10.3389/fnagi.2014.00241
Received
02 July 2014
Accepted
22 August 2014
Published
11 September 2014
Volume
6 - 2014
Edited by
P. Hemachandra Reddy, Oregen Health and Science University, USA
Reviewed by
Mario Parra, University of Edinburgh, UK; Russell H. Swerdlow, University of Kansas Medical Center, USA
Copyright
© 2014 Oishi and Lyketsos.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kenichi Oishi, The Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, 217 Traylor Building, 720 Rutland Avenue, Baltimore, MD 21205, USA e-mail: koishi@mri.jhu.edu
This article was submitted to the journal Frontiers in Aging Neuroscience.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.